<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="369733">
  <stage>Registered</stage>
  <submitdate>4/12/2015</submitdate>
  <approvaldate>10/02/2016</approvaldate>
  <actrnumber>ACTRN12616000169448</actrnumber>
  <trial_identification>
    <studytitle>Role of oral and inactivated poliovitus vaccines in inducing mucosal immunity - a trial in small children in Cuba</studytitle>
    <scientifictitle>Comparison of mucosal immunity against polioviruses induced by inactivated poliovirus vaccine alone or in combination with bivalent oral poliovirus vaccine - a trial in small children in Cuba</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>poliomyelitis</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Public Health</conditioncode1>
      <conditioncode2>Epidemiology</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>IPV: one dose (0.5 ml) of Inactivated poliovirus vaccine administered intramuscularly; tOPV: one dose (2 drops) of trivalent oral poliovirus vaccine administered orally; bOPV: one dose (2 drops) of bivalent poliovirus vaccine administered orally; all vaccines administered on-site by study staff

All Arms: blood collection at enrollment, 30 and 60 days post enrollment; stool collection 30, 37, 44 and 51 days post enrollment

Arm 1: IPV at enrollment; tOPV 30 days post enrollment
Arm 2: IPV+bOPV at enrollment, tOPV 30 days post enrollment
Arm 3: no vaccine at enrollment, tOPV 30 days post enrollment</interventions>
    <comparator>Arm 3 is reference arm.</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>difference in poliovirus shedding in stool </outcome>
      <timepoint>7 days after tOPV dose</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>difference in dynamic of poliovirus shedding after tOPV dose assessed by virus isolation in stool on days 14, 21 and 42 after tOPV dose</outcome>
      <timepoint>14, 21 and 42 days after tOPV challenge</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy infants born between June 1 and August 31, 2015 (&gt;3rd percentile for height and weight) at enrollment living within the catchments area of the participating health centers will be eligible for enrollment to Arms 1 and 2. 
Healthy infants born between November 1 and December 31, 2015 (&gt;3rd percentile for height and weight) at enrollment living within the catchments area of the participating health centers will be eligible for enrollment to Arm 3. 
</inclusivecriteria>
    <inclusiveminage>3</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>7</inclusivemaxage>
    <inclusivemaxagetype>Months</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Infants &lt;3 percentile for height and weight, residence outside the catchments area, or families expecting to move away during the study period, will be excluded. A diagnosis, suspicion or treatment of immunodeficiency disorder (either in the participant or in a member of the immediate family) will render the child ineligible for the study. Infants of mother age below legal age (&lt;18 years) or with mentally incapacity will not be eligible to participate.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>15/02/2016</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Cuba</country>
      <state>Camaguey</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>WHO</primarysponsorname>
    <primarysponsoraddress>World Health Organization
Avenue Appia 20
CH-1211 Geneva 27 Suisse
</primarysponsoraddress>
    <primarysponsorcountry>Switzerland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>WHO</fundingname>
      <fundingaddress>World Health Organization
Avenue Appia 20
CH-1211 Geneva 27 Suisse
</fundingaddress>
      <fundingcountry>Switzerland</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial will assess whether inactivated polio vaccine given as an injection together with a live polio vaccine given orally is capable of inducing immunity against poliovirus in the intestinal mucosal space (so called mucosal immunity); this knowledge will be important when deciding on outbreak response strategies in cases of poliovirus outbreaks because only mucosal immunity is capable of stopping an outbreak by preventing infected individuals from excreting poliovirus in stool and infecting others  </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>ERC Ministry of Health, Cuba</ethicname>
      <ethicaddress>World Health Organization
Avenue Appia 20
CH-1211 Geneva 27 Suisse
</ethicaddress>
      <ethicapprovaldate>8/01/2016</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>7/12/2015</ethicsubmitdate>
      <ethiccountry>Cuba</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Sonia Resik</name>
      <address>Autopista Novia del Mediodia, KM 6 1/2 La Lisa, La Habana,  CUBA</address>
      <phone>+53 72553550</phone>
      <fax />
      <email>sresik@ipk.sld.cu</email>
      <country>Cuba</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ondrej Mach</name>
      <address>World Health Organization
Avenue Appia 20
CH-1211 Geneva 27 Suisse
</address>
      <phone>+41227911863</phone>
      <fax />
      <email>macho@who.int</email>
      <country>Switzerland</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>ondrej mach</name>
      <address>World Health Organization
Avenue Appia 20
CH-1211 Geneva 27 Suisse
</address>
      <phone>+41227911863</phone>
      <fax />
      <email>macho@who.int</email>
      <country>Switzerland</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>